Adverse events (any) · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (any) · heavy menstrual bleeding
It is very uncertain whether antifibrinolytics changes adverse events (any) compared with herbal medicines (very low certainty).
1 finding from 1 review
Adverse events (any) · heavy menstrual bleeding
It is very uncertain whether antifibrinolytics changes adverse events (any) compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Adverse events (any) · women with heavy menstrual bleeding
Antifibrinolytics showed no clear difference in adverse events (any) compared with no treatment or placebo (low certainty).
1 finding from 1 review
Adverse events (any) · women with heavy menstrual bleeding
Antifibrinolytics may leads to lower adverse events (any) compared with progestogens (low certainty).
1 finding from 1 review
Any adverse events · people with cancer who have febrile neutropenia
It is very uncertain whether adverse events with anti‐gram‐positive antibiotics changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (timing not specified) · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ overall (any adverse events not specified) compared with placebo overall (moderate certainty).
1 finding from 1 review
Any adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in any adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events, any (endpoints fall between 1 6 six months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Adverse events (any) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes adverse events (any) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (any) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether probiotic changes adverse events (any) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events 49 weeks · adults with asthma
The intervention leads to lower any adverse events 49 weeks (high certainty).
1 finding from 1 review
Adverse events: Any prolactin‐related ‐ medium term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any prolactin‐related ‐ medium term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Number of any adverse events: immediately after treatment · overactive bladder
It is very uncertain whether summary of findings table ‐ Bladder training changes number of any adverse events: immediately after treatment compared with anticholinergics (very low certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Adverse events during treatment period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review